Floatz logo

ose2101

Platinum-sensitive Ovarian Cancer

ARCAGY/ GINECO GROUPvaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

524 Active assets in the Platinum-sensitive Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

ose2101 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
Locally Advanced CancerDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →